Digestive Disease Interventions 2019; 03(02): 126-132
DOI: 10.1055/s-0039-1691815
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Combined Treatments in Liver Ablations

Irene Bargellini
1   Department of Interventional Radiology, Pisa University Hospital, Pisa, Italy
,
Piercarlo Rossi
1   Department of Interventional Radiology, Pisa University Hospital, Pisa, Italy
,
Laura Crocetti
1   Department of Interventional Radiology, Pisa University Hospital, Pisa, Italy
,
Giulia Lorenzoni
1   Department of Interventional Radiology, Pisa University Hospital, Pisa, Italy
,
Elena Bozzi
1   Department of Interventional Radiology, Pisa University Hospital, Pisa, Italy
,
Alessandro Lunardi
1   Department of Interventional Radiology, Pisa University Hospital, Pisa, Italy
,
Roberto Cioni
1   Department of Interventional Radiology, Pisa University Hospital, Pisa, Italy
› Author Affiliations
Further Information

Publication History

14 January 2019

29 April 2019

Publication Date:
03 June 2019 (online)

Abstract

Percutaneous ablation is a curative treatment indicated in very early and early hepatocellular carcinoma (HCC). Procedural success remains disappointing in lesions ≥3.0 cm and located in subcapsular and perivascular areas. To overcome these limitations, combination treatments have been proposed. The combination of ablation and transarterial chemoembolization (TACE) is widely adopted in clinical practice and may improve survival, particularly in patients with single nodules 3 to 5 cm in size. However, technical issues and clinical indications are still debated. Radiofrequency ablation (RFA) may also be combined with percutaneous ethanol injection to improve local tumor control; limited data show safety and efficacy of this option. The combination of ablation and systemic treatments is still debated. Intravenous injection of thermosensitive liposomal doxorubicin in association with prolonged RFA is under investigation in patients with single lesions < 7 cm. While there is no indication for the use of systemic drugs (specifically sorafenib) in the adjuvant setting, the observation that RFA is able to activate inflammatory reactions has raised interest in the possibility of combining RFA with the new immuno-oncology drugs, for local and distant tumor control. Thus ablation would no longer be reserved only to early HCC but could be exploited also in more advanced stages.

 
  • References

  • 1 Akinyemiju T, Abera S, Ahmed M. , et al; Global Burden of Disease Liver Cancer Collaboration. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level. JAMA Oncol 2017; 3 (12) 1683-1691
  • 2 El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142 (06) 1264-1273.e1
  • 3 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 2018; 69 (01) 182-236
  • 4 Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018; 391 (10127): 1301-1314
  • 5 Serra C, Cucchetti A, Felicani C. , et al. Assessment of radiofrequency ablation efficacy for hepatocellular carcinoma by histology and pretransplant radiology. Liver Transpl 2019; 25 (01) 88-97
  • 6 Doyle A, Gorgen A, Muaddi H. , et al. Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients. J Hepatol 2019; 70 (05) 866-873
  • 7 Lam VW, Ng KK, Chok KS. , et al. Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma. J Am Coll Surg 2008; 207 (01) 20-29
  • 8 Ikeda K, Seki T, Umehara H. , et al. Clinicopathologic study of small hepatocellular carcinoma with microscopic satellite nodules to determine the extent of tumor ablation by local therapy. Int J Oncol 2007; 31 (03) 485-491
  • 9 Ünal E, İdilman İS, Akata D, Özmen MN, Karçaaltıncaba M. Microvascular invasion in hepatocellular carcinoma. Diagn Interv Radiol 2016; 22 (02) 125-132
  • 10 Bargellini I, Florio F, Golfieri R, Grosso M, Lauretti DL, Cioni R. Trends in utilization of transarterial treatments for hepatocellular carcinoma: results of a survey by the Italian Society of Interventional Radiology. Cardiovasc Intervent Radiol 2014; 37 (02) 438-444
  • 11 Shibata T, Isoda H, Hirokawa Y, Arizono S, Shimada K, Togashi K. Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment?. Radiology 2009; 252 (03) 905-913
  • 12 Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer 2010; 116 (23) 5452-5460
  • 13 Peng ZW, Zhang YJ, Chen MS. , et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol 2013; 31 (04) 426-432
  • 14 Solbiati L, Tonolini M, Cova L. Monitoring RF ablation. Eur Radiol 2004; 14 (Suppl. 08) 34-42
  • 15 Ahrar K, Newman RA, Pang J, Vijjeswarapu MK, Wallace MJ, Wright KC. 2004 Dr. Gary J. Becker Young Investigator Award: Relative thermosensitivity of cytotoxic drugs used in transcatheter arterial chemoembolization. J Vasc Interv Radiol 2004; 15 (09) 901-905
  • 16 Lencioni R, Crocetti L, Petruzzi P. , et al. Doxorubicin-eluting bead-enhanced radiofrequency ablation of hepatocellular carcinoma: a pilot clinical study. J Hepatol 2008; 49 (02) 217-222
  • 17 Iezzi R, Cesario V, Siciliani L. , et al; HepatoCATT Group for the Multidisciplinary Management of HCC. Single-step multimodal locoregional treatment for unresectable hepatocellular carcinoma: balloon-occluded percutaneous radiofrequency thermal ablation (BO-RFA) plus transcatheter arterial chemoembolization (TACE). Radiol Med (Torino) 2013; 118 (04) 555-569
  • 18 Tanaka T, Isfort P, Braunschweig T. , et al. Superselective particle embolization enhances efficacy of radiofrequency ablation: effects of particle size and sequence of action. Cardiovasc Intervent Radiol 2013; 36 (03) 773-782
  • 19 Mohamed WM, Saeed AS, Mohamed GEDE. , et al. Combined radiofrequency ablation and transarterial chemoembolization in treatment of unresectable primary liver cancer. Gastroenterol Hepatol 2015; 2 (03) 43-55
  • 20 Gadaleta C, Catino A, Ranieri G. , et al. Single-step therapy -- feasibility and safety of simultaneous transarterial chemoembolization and radiofrequency ablation for hepatic malignancies. In Vivo 2009; 23 (05) 813-820
  • 21 Sheta E, El-Kalla F, El-Gharib M. , et al. Comparison of single-session transarterial chemoembolization combined with microwave ablation or radiofrequency ablation in the treatment of hepatocellular carcinoma: a randomized-controlled study. Eur J Gastroenterol Hepatol 2016; 28 (10) 1198-1203
  • 22 Poggi G, Tosoratti N, Montagna B, Picchi C. Microwave ablation of hepatocellular carcinoma. World J Hepatol 2015; 7 (25) 2578-2589
  • 23 Martin RC, Scoggins CR, McMasters KM. Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience. Ann Surg Oncol 2010; 17 (01) 171-178
  • 24 Loriaud A, Denys A, Seror O. , et al. Hepatocellular carcinoma abutting large vessels: comparison of four percutaneous ablation systems. Int J Hyperthermia 2018; 34 (08) 1171-1178
  • 25 Vietti Violi N, Duran R, Guiu B. , et al. Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial. Lancet Gastroenterol Hepatol 2018; 3 (05) 317-325
  • 26 Knavel EM, Green CM, Gendron-Fitzpatrick A, Brace CL, Laeseke PF. Combination therapies: quantifying the effects of transarterial embolization on microwave ablation zones. J Vasc Interv Radiol 2018; 29 (07) 1050-1056
  • 27 Chen QF, Jia ZY, Yang ZQ, Fan WL, Shi HB. Transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-microwave ablation therapy for hepatocellular carcinoma tumors ≤5 cm: a propensity analysis at a single center. Cardiovasc Intervent Radiol 2017; 40 (11) 1748-1755
  • 28 Zhang R, Shen L, Zhao L, Guan Z, Chen Q, Li W. Combined transarterial chemoembolization and microwave ablation versus transarterial chemoembolization in BCLC stage B hepatocellular carcinoma. Diagn Interv Radiol 2018; 24 (04) 219-224
  • 29 Ginsburg M, Zivin SP, Wroblewski K, Doshi T, Vasnani RJ, Van Ha TG. Comparison of combination therapies in the management of hepatocellular carcinoma: transarterial chemoembolization with radiofrequency ablation versus microwave ablation. J Vasc Interv Radiol 2015; 26 (03) 330-341
  • 30 Abdelaziz AO, Abdelmaksoud AH, Nabeel MM. , et al. Transarterial chemoembolization combined with either radiofrequency or microwave ablation in management of hepatocellular carcinoma. Asian Pac J Cancer Prev 2017; 18 (01) 189-194
  • 31 Iezzi R, Pompili M, La Torre MF. , et al; HepatoCATT Study Group for the Multidisciplinary Management of HCC. Radiofrequency ablation plus drug-eluting beads transcatheter arterial chemoembolization for the treatment of single large hepatocellular carcinoma. Dig Liver Dis 2015; 47 (03) 242-248
  • 32 Lu Z, Wen F, Guo Q, Liang H, Mao X, Sun H. Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: a meta-analysis of randomized-controlled trials. Eur J Gastroenterol Hepatol 2013; 25 (02) 187-194
  • 33 Ni JY, Liu SS, Xu LF, Sun HL, Chen YT. Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2013; 19 (24) 3872-3882
  • 34 Yan S, Xu D, Sun B. Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis. Dig Dis Sci 2013; 58 (07) 2107-2113
  • 35 Chen QW, Ying HF, Gao S. , et al. Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2016; 40 (03) 309-314
  • 36 Wang Y, Deng T, Zeng L, Chen W. Efficacy and safety of radiofrequency ablation and transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: A meta-analysis. Hepatol Res 2016; 46 (01) 58-71
  • 37 Yang DJ, Luo KL, Liu H. , et al. Meta-analysis of transcatheter arterial chemoembolization plus radiofrequency ablation versus transcatheter arterial chemoembolization alone for hepatocellular carcinoma. Oncotarget 2017; 8 (02) 2960-2970
  • 38 Katsanos K, Kitrou P, Spiliopoulos S, Maroulis I, Petsas T, Karnabatidis D. Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: a network meta-analysis of randomized controlled trials. PLoS One 2017; 12 (09) e0184597
  • 39 Yi PS, Huang M, Zhang M, Xu L, Xu MQ. Comparison of transarterial chemoembolization combined with radiofrequency ablation therapy versus surgical resection for early hepatocellular carcinoma. Am Surg 2018; 84 (02) 282-288
  • 40 Kurokohchi K, Watanabe S, Masaki T. , et al. Combined use of percutaneous ethanol injection and radiofrequency ablation for the effective treatment of hepatocelluar carcinoma. Int J Oncol 2002; 21 (04) 841-846
  • 41 Vallone P, Catalano O, Izzo F, Siani A. Combined ethanol injection therapy and radiofrequency ablation therapy in percutaneous treatment of hepatocellular carcinoma larger than 4 cm. Cardiovasc Intervent Radiol 2006; 29 (04) 544-551
  • 42 Wong SN, Lin CJ, Lin CC, Chen WT, Cua IH, Lin SM. Combined percutaneous radiofrequency ablation and ethanol injection for hepatocellular carcinoma in high-risk locations. AJR Am J Roentgenol 2008; 190 (03) W187-W195
  • 43 Ren H, Liang P, Yu X, Wang Y, Lu T, Li X. Treatment of liver tumours adjacent to hepatic hilum with percutaneous microwave ablation combined with ethanol injection: a pilot study. Int J Hyperthermia 2011; 27 (03) 249-254
  • 44 Huang G, Lin M, Xie X. , et al. Combined radiofrequency ablation and ethanol injection with a multipronged needle for the treatment of medium and large hepatocellular carcinoma. Eur Radiol 2014; 24 (07) 1565-1571
  • 45 Chen S, Peng Z, Lin M. , et al. Combined percutaneous radiofrequency ablation and ethanol injection versus hepatic resection for 2.1-5.0 cm solitary hepatocellular carcinoma: a retrospective comparative multicentre study. Eur Radiol 2018; 28 (09) 3651-3660
  • 46 Zhang YJ, Liang HH, Chen MS. , et al. Hepatocellular carcinoma treated with radiofrequency ablation with or without ethanol injection: a prospective randomized trial. Radiology 2007; 244 (02) 599-607
  • 47 Liang HH, Chen MS, Peng ZW. , et al. Percutaneous radiofrequency ablation versus repeat hepatectomy for recurrent hepatocellular carcinoma: a retrospective study. Ann Surg Oncol 2008; 15 (12) 3484-3493
  • 48 Li Z, Zhang K, Lin SM. , et al. Radiofrequency ablation combined with percutaneous ethanol injection for hepatocellular carcinoma: a systematic review and meta-analysis. Int J Hyperthermia 2017; 33 (03) 237-246
  • 49 Zhu ZX, Liao MH, Wang XX, Huang JW. Radiofrequency ablation with or without ethanol injection for hepatocellular carcinoma: a systematic review and meta-analysis. Minerva Med 2016; 107 (06) 381-391
  • 50 Chen S, Peng Z, Xiao H. , et al. Combined radiofrequency ablation and ethanol injection versus repeat hepatectomy for elderly patients with recurrent hepatocellular carcinoma after initial hepatic surgery. Int J Hyperthermia 2018; 34 (07) 1029-1037
  • 51 Ahmed M, Monsky WE, Girnun G. , et al. Radiofrequency thermal ablation sharply increases intratumoral liposomal doxorubicin accumulation and tumor coagulation. Cancer Res 2003; 63 (19) 6327-6333
  • 52 Ahmed M, Moussa M, Goldberg SN. Synergy in cancer treatment between liposomal chemotherapeutics and thermal ablation. Chem Phys Lipids 2012; 165 (04) 424-437
  • 53 Tak WY, Lin SM, Wang Y. , et al. Phase III HEAT study adding lyso-thermosensitive liposomal doxorubicin to radiofrequency ablation in patients with unresectable hepatocellular carcinoma lesions. Clin Cancer Res 2018; 24 (01) 73-83
  • 54 Swenson CE, Haemmerich D, Maul DH, Knox B, Ehrhart N, Reed RA. Increased duration of heating boosts local drug deposition during radiofrequency ablation in combination with thermally sensitive liposomes (ThermoDox) in a porcine model. PLoS One 2015; 10 (10) e0139752
  • 55 Xu M, Xie XH, Xie XY. , et al. Sorafenib suppresses the rapid progress of hepatocellular carcinoma after insufficient radiofrequency ablation therapy: an experiment in vivo. Acta Radiol 2013; 54 (02) 199-204
  • 56 Kong WT, Cai H, Tang Y, Zhang XL, Wang WP. Microwave coagulation/ablation in combination with sorafenib suppresses the overgrowth of residual tumor in VX2 liver tumor model. Discov Med 2016; 21 (118) 459-468
  • 57 Kan X, Jing Y, Wan QY. , et al. Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma. Eur Rev Med Pharmacol Sci 2015; 19 (02) 247-255
  • 58 Feng X, Xu R, Du X. , et al. Combination therapy with sorafenib and radiofrequency ablation for BCLC Stage 0-B1 hepatocellular carcinoma: a multicenter retrospective cohort study. Am J Gastroenterol 2014; 109 (12) 1891-1899
  • 59 Bruix J, Takayama T, Mazzaferro V. , et al; STORM investigators. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 2015; 16 (13) 1344-1354
  • 60 Pinyol R, Montal R, Bassaganyas L. , et al. Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. Gut 2018;(e-pub ahead of print)
  • 61 Giorgio A, Merola MG, Montesarchio L. , et al. Sorafenib combined with radio-frequency ablation compared with sorafenib alone in treatment of hepatocellular carcinoma invading portal vein: a Western randomized controlled trial. Anticancer Res 2016; 36 (11) 6179-6183
  • 62 Peng Z, Chen S, Wei M. , et al. Advanced recurrent hepatocellular carcinoma: treatment with sorafenib alone or in combination with transarterial chemoembolization and radiofrequency ablation. Radiology 2018; 287 (02) 705-714
  • 63 Chu KF, Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer 2014; 14 (03) 199-208
  • 64 Rozenblum N, Zeira E, Scaiewicz V. , et al. Oncogenesis: an “off-target” effect of radiofrequency ablation. Radiology 2015; 276 (02) 426-432
  • 65 Ahmed M, Kumar G, Moussa M. , et al. Hepatic radiofrequency ablation–induced stimulation of distant tumor growth is suppressed by c-Met inhibition. Radiology 2016; 279 (01) 103-117
  • 66 Ahmed M, Kumar G, Navarro G. , et al. Systemic siRNA nanoparticle-based drugs combined with radiofrequency ablation for cancer therapy. PLoS One 2015; 10 (07) e0128910
  • 67 Kumar G, Goldberg SN, Wang Y. , et al. Hepatic radiofrequency ablation: markedly reduced systemic effects by modulating periablational inflammation via cyclooxygenase-2 inhibition. Eur Radiol 2017; 27 (03) 1238-1247
  • 68 Duffy AG, Ulahannan SV, Makorova-Rusher O. , et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol 2017; 66 (03) 545-551
  • 69 Gerbes A, Zoulim F, Tilg H. , et al. Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma. Gut 2018; 67 (02) 380-388